Science & Enterprise subscription

Follow us on Twitter

  • A new company, spun off from university biomedical engineering labs, is creating cancer diagnostics by analyzing mi…
    about 7 hours ago
  • New post on Science and Enterprise: Start-Up Developing Microbial Cancer Detection Tests #Science #Business
    about 7 hours ago
  • An NIH award to a biotechnology company funds discovery of drugs that protect brain cells from degenerative disorde…
    about 13 hours ago
  • New post on Science and Enterprise: Small Biz Grant Advances Neuro Protection Drugs #Science #Business
    about 13 hours ago
  • Why we stopped dynamic banner ads on Science and Enterprise
    about 17 hours ago

Please share Science & Enterprise

Infographic – Growing Interest in Longevity Research

Chart: human longevity references

News references to terms related to human longevity, Sept 2013 to Aug. 2018. Click on chart for full-size view. (CB Insights)

3 Nov. 2018. Most of the reporting in Science & Enterprise is about biomedical research and development, with much of that work addressing the needs of an aging population worldwide.In fact, a company founded by genomics pioneer J. Craig Venter has the name Human Longevity Inc., on which we reported several times, including earlier this year. And this interest in extending people’s lifetimes, as well as improving the quality of their lives, drives much of the venture and other business investment in R&D.

Our friends at the technology intelligence company CB Insights also reported recently on this phenomenon, with a chart from that report showing a growing journalistic interest in topics related to human longevity, this weekend’s infographic. The graphic displays the number of news references citing terms like senescence — the process of deterioration due to age — or age-related diseases between September 2013 and August 2018. The data show two big spikes in interest, in early 2017 and just this past year.

This growing interest is also reflected by investors. The links below from recent Science & Enterprise stories offer examples of those investments just in neurodegenerative disorders associated with aging, reaching in some cases into billions of dollars.

More from Science & Enterprise:

*     *     *

Comments are closed.